A 55-year-old woman with newly diagnosed myasthenia gravis is started on pyridostigmine 60 mg orally four times daily. After 3 days, she develops severe abdominal cramping, diarrhea, and muscle weakness that worsens throughout the day. Her family reports that she is now unable to climb stairs or lift her arms. On examination, she has visible muscle fasciculations in her limbs, miosis, and profuse salivation. Her vital signs show heart rate 52 bpm and blood pressure 138/88 mmHg. Which of the following is the most appropriate immediate management?

Explanation

## Clinical Presentation: Cholinergic Crisis This patient has developed **cholinergic crisis** — a medical emergency caused by excessive cholinergic stimulation from anticholinesterase overdose or overuse. ### Diagnostic Features Present **Muscarinic signs (SLUDGE mnemonic):** - **S**alivation (profuse) - **L**acrimation (implied by eye involvement) - **U**rination (diarrhea = GI component) - **D**efecation (abdominal cramping, diarrhea) - **G**I upset (cramping) - **E**mesis (potential) **Nicotinic signs:** - Muscle fasciculations (visible) - Muscle weakness (worsening throughout the day — hallmark of cholinergic crisis) - Bradycardia (52 bpm) **High-Yield:** The **progressive worsening of weakness** despite drug administration is the key diagnostic clue. In myasthenic crisis, weakness is due to insufficient acetylcholine; in cholinergic crisis, weakness is due to **excessive** acetylcholine causing depolarization blockade at the neuromuscular junction. ### Why Atropine Is First-Line **Key Point:** Atropine is a **competitive muscarinic antagonist** that blocks excess acetylcholine at muscarinic receptors. It provides rapid symptomatic relief of muscarinic manifestations (salivation, diarrhea, bradycardia, miosis). **Clinical Pearl:** Atropine does NOT directly address nicotinic signs (fasciculations, weakness) because it does not block nicotinic receptors. However, stopping the offending drug (pyridostigmine) and providing supportive care (including ventilatory support if needed) allows the crisis to resolve. ### Management Algorithm for Cholinergic Crisis ```mermaid flowchart TD A[Suspected Cholinergic Crisis]:::outcome --> B[STOP anticholinesterase immediately]:::urgent B --> C[Atropine 0.5-1 mg IV bolus]:::action C --> D{Respiratory compromise or severe weakness?}:::decision D -->|Yes| E[Intubate + mechanical ventilation]:::action D -->|No| F[Supportive care, continuous monitoring]:::action E --> G{Nicotinic signs persist after atropine?}:::decision F --> G G -->|Yes| H[Pralidoxime 1-2 g IV]:::action G -->|No| I[Observation, repeat atropine as needed]:::action H --> I ``` **Tip:** Atropine can be repeated every 5–10 minutes if needed, titrated to heart rate and salivation. Pralidoxime is added only if nicotinic signs (fasciculations, weakness) persist despite atropine and discontinuation of the anticholinesterase. ## Why Each Alternative Is Wrong | Option | Why It's Wrong | |--------|---------------| | **Increase dose** | Increasing pyridostigmine in cholinergic crisis is dangerous — it worsens the crisis. The problem is excess drug, not insufficient dose. | | **Edrophonium test** | Edrophonium is a diagnostic tool used in stable patients to differentiate myasthenic from cholinergic crisis. In an acute crisis with respiratory compromise risk, it is contraindicated and would worsen the condition. | | **Pralidoxime alone** | Pralidoxime reactivates acetylcholinesterase and addresses nicotinic signs, but it does NOT block muscarinic effects (salivation, diarrhea, bradycardia). Atropine must be given first for rapid muscarinic symptom relief. | [cite:KD Tripathi 8e Ch 6]